LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advanced non-small cell lung cancer that has spread to other parts of the body. The primary goals of the study are to assess overall survival and progression-free survival. Secondary objectives include analyzing outcomes based on the specific histology (subtype) of the lung cancer.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
Plus 1 other study approaches.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Oct 6, 2026 · Source: ClinicalTrials.gov
The study is currently accepting participants.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 3
- Sponsor
- NovoCure GmbH
- Interventions being studied
- Device: NovoTTF-200T; Drug: Pembrolizumab; Drug: Platinum based chemotherapy
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- ≥22 years of age in the USA ≥18 years of age outside of the USA.
- Histologically or cytologically diagnosis of stage 4 (according to Version 8 of the American Joint Committee on Cancer \[AJCC\] criteria) non-squamous or squamous NSCLC.
- Evaluable (measurable or non-measurable) disease in the thorax per RECIST v1.1.
- Have not received prior systemic treatment for their metastatic NSCLC. Subjects who received adjuvant, neoadjuvant chemotherapy or chemoradiotherapy with curative intent for non-metastatic disease are eligible if the therapy was completed at least 12 months prior to the development of metastatic disease.
- ECOG Performance Status (PS) of 0-1.
- Adequate hematologic and end-organ function o For subjects not receiving therapeutic anticoagulation: INR or aPTT ≤ 1.5 x ULN (unless participant is receiving anticoagulant therapy as long as INR or aPTT is within therapeutic range of intended use of anticoagulants).
- A female participant is eligible to participate if she is not pregnant, not breastfeeding
- If male subject with a female partner(s) of child-bearing potential, must agree to use an effective contraception
- All subjects must sign written informed consent.
All individuals meeting any of the following
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Central Alabama ResearchBirmingham, Alabama
- Western Regional Medical Center, LLCGoodyear, Arizona
- St. Jude Herritage Medical GroupFullerton, California
- Hoag Family Cancer Institute - Hoag Memorial HospitalNewport Beach, California
- Sutter Institute for Medical ResearchSacramento, California
- Baptist MD Anderson Cancer Center, Baptist HealthJacksonville, Florida
- Florida Cancer Affiliates - Ocala OncologyOcala, Florida
- Moffitt Cancer CenterTampa, Florida
- Northwest Oncology & HematologyBarrington, Illinois
- Elmhurst Hospital Nancy Knowles Cancer CenterElmhurst, Illinois
- Edward Cancer CenterNaperville, Illinois
- Cancer Treatment Centers of America (CTCA)Zion, Illinois
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 6, 2026. Always confirm current availability with the study team.